Search
Cefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined. … [L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.
Categories: Compounds used in a research, industrial, or household settingCrotamiton
go.drugbank.com/drugs/DB00265ApprovedCrotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. … It is miscible with alcohol and with methanol.
Categories: Compounds used in a research, industrial, or household settingProducts: A-Bite Cream, CROTAMITON LOCION AL 10 %Daprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigational[A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin … [A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia.
Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-Tolfenamic acid
go.drugbank.com/drugs/DB09216Approved[L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … [A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]
PI-166
go.drugbank.com/drugs/DB05859ExperimentalPI-166 is a small organic compound with specific avidity to liver cancer cells. … It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.
Anthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin is also known as dithranol. It is a main active ingredient in topical skin formulations for the treatment of psoriasis. … Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago.
Chlorobutanol
go.drugbank.com/drugs/DB11386ApprovedVet approvedWithdrawnChlorobutanol is a common detergent preservative in eye drops and other ophthalmic therapeutic formulations [A32744]. … Similar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone.
Categories: Compounds used in a research, industrial, or household settingPhenylbutyric acid
go.drugbank.com/drugs/DB06819ApprovedInvestigationalPhenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation. … It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone.
Synonyms: 4-Phenyl-n-butyric acid, γ-Phenyl-n-butyric acidCategories: Ammonium Ion Binding ActivityOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin … [A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022.